Cancer survivors are at greater risk of recurrent disease, development of new cancers, and long-term morbidity as compared to those without a cancer diagnosis, likely because of factors associated with their disease, its treatment, and unhealthy lifestyle behaviors (e.g., obesity, lack of physical activity) (Centers for Disease Control and Prevention [CDC], 2012). Consequently, oncology professionals should develop cancer survivorship programs that help prevent or reduce risks of new or recurrent cancers, provide cancer surveillance, and assess for late psychosocial and medical effects of cancer and its treatment; they should also intervene as needed (CDC, 2012; Hewitt, Greenfield, & Stovall, 2006).

Awareness of sarcopenic obesity and its importance in a survivor’s optimal physical function could play a significant role in survivorship programs. Sarcopenic obesity is a loss of muscle mass (sarcopenia) coupled with an increase in fat mass (obesity) (Fielding et al., 2011). This dual condition can synergistically exacerbate functional decline and negatively affect health and quality of life more than obesity or sarcopenia alone (Batsis et al., 2013). Sarcopenic obesity can be caused by aging and the effects of disease or treatment, and it escalates the risks of toxicity, morbidity, and mortality in adult cancer survivors (Chung, Kang, Lee, Lee, & Lee, 2013; Del Fabbro et al., 2012). Ormsbee et al. (2014) hypothesized that sarcopenic obesity may be present in more individuals at diagnosis of conditions like cancer than in those without disease. Other researchers have found that weight gain because of chemotherapy for breast cancer shows a distinctive pattern of sarcopenic obesity in women undergoing treatment (Markes, Brockow, & Resch, 2006). Despite its clinical importance, sarcopenic obesity is under-recognized (Batsis et al., 2013; Chung et al., 2013).

Background

Body mass index (BMI) alone is not sensitive enough to identify muscle wasting, obesity, or sarcopenic obesity,